Therefore, palmitoylation appears to be exclusively confined to mutant EGFR suggesting that, in TKI‐resistant NSCLC, the structure of mutant EGFR and/or interaction with effector protein/s may have influenced its palmitoylation. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.